Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
QNRX
QNRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
QNRX News
Quoin Establishes Subsidiary in Japan to Advance QRX003 Commercialization
3d ago
Newsfilter
Quoin Pharmaceuticals Receives Orphan Drug Designation in Japan for QRX003
Jun 05 2026
NASDAQ.COM
Japan Grants Orphan Drug Designation to QRX003
Jun 04 2026
Newsfilter
Quoin Submits First IND Application for Peeling Skin Syndrome
Jun 02 2026
Newsfilter
Quoin Pharmaceuticals Q1 Earnings Beat Expectations
May 07 2026
seekingalpha
Quoin Pharmaceuticals Provides Clinical Update on QRX009 Development
Apr 29 2026
NASDAQ.COM
Quoin Pharmaceuticals Initiates Multiple Clinical Studies for QRX009
Apr 28 2026
Newsfilter
Quoin Pharmaceuticals Initiates Multiple Clinical Studies for QRX009
Apr 28 2026
Newsfilter
Biotech Landscape Update: Regulatory Approvals and Mergers
Mar 27 2026
NASDAQ.COM
Quoin Pharmaceuticals Q4 Earnings Beat Expectations
Mar 26 2026
seekingalpha
Quoin Pharmaceuticals Provides Clinical Update on QRX003
Mar 26 2026
NASDAQ.COM
Quoin Pharmaceuticals Shares Surge 20% on FDA Feedback for QRX003
Mar 25 2026
stocktwits
QNRX Shares Jump 20% in Pre-Market Trading – FDA's Comments on Netherton Syndrome Treatment?
Mar 25 2026
stocktwits
Quoin Pharmaceuticals Advances FDA Approval Process for QRX003
Mar 25 2026
Newsfilter
Quoin Pharmaceuticals Advances NETHERTON NOW Awareness Campaign
Feb 26 2026
Newsfilter
Quoin Pharmaceuticals Files for Breakthrough Designation for QRX003, Potential First Treatment for Netherton Syndrome
Jan 20 2026
Globenewswire
Show More News
